Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.3052W HIGH $83.86
Volume
27.91 M
Value Traded
1.96 B
Short % Float
10.36%
Days to Cover
2.5
-8.97%Week
+34.06%1 Month
+127.42%3 Month
+174.75%6 Month
+176.47%5 Year
+176.47%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.43 B
EPS (TTM)
-2.99
P/E Ratio
-
Ent. Value
6.98 B
Total Shares
105.06 M
Float Shares
46.05 M
Insiders
51.74%
Institutions
38.80%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
MTSR Catalyst Timeline
Dated clinical, regulatory and corporate events for Metsera, Inc.
Past FDA Catalysts and PDUFA Decisions
How MTSR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MET097 Small moleculeCompletedNCT07311850 | Obesity and Overweight | Phase 1/2 | ACTIVE NOT_RECRUITING | 3,698 | Apr 25, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every MTSR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MET-097i | obesity | Phase 2b | 2025-09-29 | weight loss: 14.1%; nausea: 13%; vomiting: 11%; study discontinuation: 2.9%Read More | Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| FMR LLC10% Owner, See Remark 1 | Sell | -193 2,356,081 held | $61.23 | 11/03/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in MTSR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| VR Adviser, LLC | 11 % (37.5 %) | 196.27 M | 3.75 M |
Ownership Trends
MTSR Short Interest
Shares sold short, counted twice a month.
10.36%
Short % of Float
of tradable shares sold short
4.8M
Shares Sold Short
-2.1% vs prior count
2.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MTSR ranks across every disease it competes in
Competitive Position is a premium feature
See how MTSR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMTSR News
About Metsera, Inc.
Founded2025
BIOPHARMAWATCH ELITE PLUS
Trade the next MTSR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime